Top Abstract Purchase Related
Home
>
Node
>
Subnode

Effect of high dose tamoxifen therapy in conservative treatment of patients with III-IV stages of non-small cell lung cancer

Kadzhoian, A.V.; Shevchenko, A.I.

Likars'ka Sprava 2014(1-2): 103-110

2014

ISSN/ISBN: 1019-5297
PMID: 24908970
Document Number: 671936
Lung cancer is currently the leading cause of cancer-related death. The effectiveness of treatment of locally advanced and metastatic non-small cell lung cancer (NSCLC) remains low. One the promising new directions in NSCLC treatment is the inclusion of antiestrogens (tamoxifen) to standard chemotherapy regimens. Expression of estrogen (Eralpha) and progesterone (PR) receptors in the tumor tissue, objective effect and NSCLC patients' survival at chemohormonal treatment with tamoxifen use were analysed. ERalpha and PR-receptor status study in patients with NSCLC revealed presence of expression only in 1 (2%) patient. One-year and median survival (55% and 13.1 months respectively) at high-dose tamoxifen therapy use in combination with chemotherapy were established to be significantly higher (P = 0,00055) than in patients, which received only chemotherapy (32% and 9.5 months respectively).

Document emailed within 1 workday
Secure & encrypted payments

Socinski, M.A.; Shea, T.C. 1997: High-dose therapy with carboplatin and paclitaxel in non-small cell lung cancer Seminars in Oncology 24(4 Suppl 12: S12
Luikart, S.D.; Propert, K.J.; Modeas, C.R.; Green, M.R.; Perry, M.C. 1987: High-dose etoposide therapy for extensive small cell lung cancer: a Cancer and Leukemia Group B Study Cancer Treatment Reports 71(5): 533-534
Nakano, K.; Yamamoto, M.; Iwamoto, H.; Hiramoto, T. 2003: Daily low-dose cisplatin plus concurrent high-dose thoracic radiotherapy in elderly patients with locally advanced unresectable non-small-cell lung cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 30(9): 1283-1287
Ziske, C.; Gorschlüter, M.; Mey, U.; Offergeld, R.; Glasmacher, A.; Schmidt-Wolf, I.G.H. 2002: Sequential high-dose chemotherapy with autologous stem cell support in patients with limited-stage small cell lung cancer Anticancer Research 22(6b): 3723-3726
Mariotta, S.; Sposato, B.; Li Bianchi, E.; Fiorucci, F.; Ricci, A.; Carbone, F.; Crescenzi, M.; Schmid, G. 2002: Combined treatment in advanced stages (IIIb-IV) of non-small cell lung cancer European Review for Medical and Pharmacological Sciences 6(2-3): 49-54
Akbiyik, N.; Alexander, L.L. 1986: Cure rates in small cell and non-small cell carcinoma of the lung utilizing high-dose radiotherapy and chemotherapy Journal of the National Medical Association 78(3): 219-223
Rosell, R.; Gómez-Codina, J.; Anton, A.; Sánchez, J.J.; Vadell, C. 1994: Escalating high-dose epirubicin plus cisplatin in small cell lung cancer with granulocyte-macrophage colony-stimulating factor use when appropriate Seminars in Oncology 21(1 Suppl 1: 48-53
Palmer, A.J.; Brandt, A. 1996: The cost-effectiveness of four cisplatin-containing chemotherapy regimens in the treatment of stages IIi B and IV non-small cell lung cancer: an Italian perspective Monaldi Archives for Chest Disease 51(4): 279-288
Hayakawa, K.; Mitsuhashi, N.; Saito, Y.; Takahashi, M.; Katano, S.; Shiojima, K.; Furuta, M.; Niibe, H. 1993: Effect of krestin (PSK) as adjuvant treatment on the prognosis after radical radiotherapy in patients with non-small cell lung cancer Anticancer Research 13(5c): 1815-1820
Bianco, V.; Rozzi, A.; Tonini, G.; Santini, D.; Magnolfi, E.; Vincenzi, B.; D'Angelillo, R.; Marchei, P. 2002: Gemcitabine as single agent chemotherapy in elderly patients with stages III-IV non-small cell lung cancer (NSCLC): a phase Ii study Anticancer Research 22(5): 3053-3056
Neill, H.B.; Miller, A.A.; Clamon, G.H.; Perry, M.C.; Crawford, J.; Green, M.R. 1997: A phase Ii study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer Seminars in Oncology 24(4 Suppl 12: S12
Boven, E.; Tierie, A.H.; Stam, J.; Pinedo, H.M. 1988: Combined radiation therapy and daily low-dose cisplatin for inoperable, locally advanced non-small cell lung cancer: results of a phase Ii trial Seminars in Oncology 15(6 Suppl 7: 18-19
Chen, Y.M.; Perng, R.P.; Yang, K.Y.; Wu, H.W.; Lin, W.C.; Liu, J.M.; Tsai, C.M.; Whang-Peng, J. 2000: Combination chemotherapy with tamoxifen, ifosfamide, epirubicin and cisplatin in extensive-disease small-cell lung cancer Zhonghua Yi Xue Za Zhi 63(8): 605-611
Hashizume, T.; Ogura, T.; Kozawa, S.; Kobayashi, N.; Tagawa, A.; Miyazawa, N.; Watanuki, Y.; Takahashi, H. 2006: Gefitinib as a first-line therapy in patients with advanced non-small cell lung cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 33(4): 467-470
Ettinger, D.S.; Karp, J.E.; Abeloff, M.D.; Burke, P.J.; Braine, H.G. 1978: Intermittent high-dose cyclophosphamide chemotherapy for small cell carcinoma of the lung Cancer Treatment Reports 62(3): 413-424
Cohen, B.R.; Bailey, T.D.; Talkington, A.A.; Wolff, A.D. 1994: Radiation therapy for stage IIi non-small cell lung cancer: a curative treatment option West Virginia Medical Journal 90(1): 8-12
John, L.D. 2001: Quality of life in patients receiving radiation therapy for non-small cell lung cancer Oncology Nursing Forum 28(5): 807-813
Cohen, M.H. 1983: Is thoracic radiation therapy necessary for patients with limited-stage small cell lung cancer? no Cancer Treatment Reports 67(3): 217-221
Dahse, R.; Berndt, A.; Kosmehl, H. 2008: PCR-based testing for therapy-related EGFR mutations in patients with non-small cell lung cancer Anticancer Research 28(4b): 2265-2270
Cataldo, I.; Bedini, A.V.; Muscolino, G.; Valente, M.; Pastorino, U.; Bidoli, P.; Pilotti, S.; Ravasi, G. 1989: Surgical resection in the treatment of stages I-II of small cell lung carcinoma (SCLC) Tumori 75(1): 28-30